Par Ebitda from 2010 to 2024
| PAR Stock | 294.05 12.65 4.50% |
EBITDA | First Reported 2018-06-30 | Previous Quarter 43.1 M | Current Value 123.9 M | Quarterly Volatility 21.9 M |
Check Par Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Par Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 M, Total Revenue of 669.2 M or Gross Profit of 555.6 M, as well as many indicators such as . Par financial statements analysis is a perfect complement when working with Par Drugs Valuation or Volatility modules.
Par | Ebitda |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Par Stock
Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.